Crohn’s/Colitis Drug Copay Assistance For Medicare, Medicaid Enrollees Cleared By OIG
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS Office of Inspector General concludes a charitable organization’s proposed copay assistance program for patients with Crohn’s disease and ulcerative colitis may be offered to enrollees in Medicare and Medicaid without violating federal anti-kickback laws.
You may also be interested in...
Manufacturer Patient Assistance Programs To Change Following IG Guidance
An HHS Office of Inspector General "1special advisory bulletin" on manufacturer-sponsored patient assistance programs for Medicare Part D beneficiaries will force companies to restructure these programs
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.